The 1p/19q codeletion, MGMT promoter methylation and IDH1/IDH2 mutation are well-established prognostic factors, but a number of critical issues remain to be solved. The recent development of 1p ...

As part of the Agios deal Servier also took rights to vorasidenib – a dual inhibitor of mutated IDH1 and IDH2 – that is in trials for a hard-to-treat form of brain cancer called glioma.

With its ability to specifically inhibit the mutant IDH1 enzyme, TIBSOVO addresses an unmet need in personalized cancer treatment, offering new hope for patients with limited options. As clinical ...

is being marketed as Voranigo for patients aged 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. Specifically, it can be used after ...